Treatment of alcoholic hepatitis.
Alcoholic hepatitis is a common disease with an overall 1-year mortality of 20%. Although the classical treatment for alcoholic hepatitis is abstinence, in some individuals abstinence alone is inadequate to promote survival and recovery. This is particularly true of patients with severe alcoholic hepatitis, who are identified by jaundice, coagulopathy and neutrophilia. Within the last two decades, several agents have been examined as treatments for alcoholic hepatitis and cirrhosis. They have targeted several key processes in the pathophysiology of alcoholic liver disease, including hypermetabolism, inflammation, cytokine dysregulation and oxidant stress. The compounds that offer the greatest survival benefit to patients with severe alcoholic hepatitis are corticosteroids. Several groups have reported excellent results with corticosteroids, but positive results are not uniform, and there remains some controversy over their efficacy. Even if corticosteroids are beneficial for alcoholic hepatitis, they are not recommended for all patients at risk. Consequently, other agents are being tested that have broader applicability to individuals with contraindications to steroids. In this regard, pentoxifylline shows some promise, as does enteral feeding with medium chain triglycerides. Independent efforts are also being directed toward treatment of chronic alcoholic liver disease and alcoholic cirrhosis. Anti-oxidants have received the greatest attention; drugs such as S-adenosyl-methionine may be of benefit. This and others are under active study.
Maher
Jacquelyn J
JJ
Liver Center Laboratory, Department of Medicine, University of California-San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA. jmaher@medsfgh.ucsf.edu
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D006519:Hepatitis, Alcoholic / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation; D010431:Pentoxifylline / Q000627:therapeutic use; D011441:Propylthiouracil / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000963:Antimetabolites; D000975:Antioxidants; D011441:Propylthiouracil; D010431:Pentoxifylline; D003078:Colchicine